The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient out-of-pocket savings with lower-dose trastuzumab.
 
Marie S. Dreyer
No Relationships to Disclose
 
Alec Kacew
No Relationships to Disclose
 
Po-Hung Hsieh
Patents, Royalties, Other Intellectual Property - University of North Carolina Chapel Hill/Glycan Therapeutics, LLC
 
Anthony Serritella
No Relationships to Disclose
 
Randall W. Knoebel
No Relationships to Disclose
 
Rita Nanda
Consulting or Advisory Role - Aduro Biotech; Athenex; Daiichi Sankyo; Genentech/Roche; Immunomedics; ION Pharma; Macrogenics; Merck; Pfizer; Seagen
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Other Relationship - G1 Therapeutics
 
Garth William Strohbehn
Patents, Royalties, Other Intellectual Property - IP related to low-dose tocilizumab in Covid-19
Other Relationship - Abbott Laboratories (Inst)
 
Mark J. Ratain
Consulting or Advisory Role - Apotex; Aptevo Therapeutics; Arvinas; Ayala Pharmaceuticals; Genentech; Oncovalent Therapeutics; Pneuma Respiratory
Research Funding - Abbvie (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech/Roche (Inst); Incyte (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Provisional patent application for method of treating viral pneumonitis with low-dose tocilizumab (Inst); royalties related to UGT1A1 genotyping for irinotecan; royalties related to UGT1A1 genotyping for irinotecan (Inst)
Expert Testimony - Multiple generic companies (defendants in patent litigation)
Other Relationship - BeiGene; Value in Cancer Care Consortium